Caroline Pettenati1, Yann Neuzillet2, Camelia Radulescu2, Jean-Marie Hervé2, Vincent Molinié3, Thierry Lebret2. 1. Department of Urology and Pathology, Hospital Foch, University of Versailles-Saint-Quentin-en-Yvelines (UVSQ), 40 rue Worth, 92151, Suresnes, France. pettenati.c@gmail.com. 2. Department of Urology and Pathology, Hospital Foch, University of Versailles-Saint-Quentin-en-Yvelines (UVSQ), 40 rue Worth, 92151, Suresnes, France. 3. Department of Pathology, Fort de France University Hospital, Fort de France, France.
Abstract
PURPOSE: Positive surgical margins (PSMs) after radical prostatectomy (RP) are a known factor associated with biochemical recurrence (BCR) and raise the issue of adjuvant treatment by radiotherapy versus salvage treatment at recurrence. To help this choice, our study aimed to analyze BCR-free survival and factors associated with BCR in patients with PSM and undetectable postoperative prostate-specific antigen (PSA). METHODS: Between 2005 and 2008, 630 patients had RP for localized prostate cancer in our center. We included patients with PSM, uninvaded nods, undetectable postoperative PSA and no adjuvant treatment. The 5-year BCR-free survival was calculated using Kaplan-Meier method. Logistic regression models were used to determine the factors associated with BCR in univariate and multivariate analyses (Cox model). RESULTS: The PSM rate was 32.7 % (n = 206 patients), and 110 patients corresponded to the inclusion criteria. The median follow-up was 72 months. The BCR rate was 30 % with a 5-year BCR-free survival of 83.9 %. The factors significantly associated with BCR were preoperative PSA, predominance and percentage of Gleason 4, tumor volume, PSM length and predominance of Gleason 4 at the margin. In the multivariate analysis, the remaining two significant factors were PSM length [OR 4.35, 95 % CI (1.011-1.421), p = 0.037] and tumor volume [OR 4.29, 95 % CI (1.011-1.483), p = 0.038]. CONCLUSION: Over a 5-year follow-up, only one-third of patients experienced BCR. It might be reasonable to postpone adjuvant radiotherapy for patients with PSM and undetectable PSA after RP. Tumor volume and PSM length were associated with BCR and should be taken into account in the postoperative treatment management.
PURPOSE: Positive surgical margins (PSMs) after radical prostatectomy (RP) are a known factor associated with biochemical recurrence (BCR) and raise the issue of adjuvant treatment by radiotherapy versus salvage treatment at recurrence. To help this choice, our study aimed to analyze BCR-free survival and factors associated with BCR in patients with PSM and undetectable postoperative prostate-specific antigen (PSA). METHODS: Between 2005 and 2008, 630 patients had RP for localized prostate cancer in our center. We included patients with PSM, uninvaded nods, undetectable postoperative PSA and no adjuvant treatment. The 5-year BCR-free survival was calculated using Kaplan-Meier method. Logistic regression models were used to determine the factors associated with BCR in univariate and multivariate analyses (Cox model). RESULTS: The PSM rate was 32.7 % (n = 206 patients), and 110 patients corresponded to the inclusion criteria. The median follow-up was 72 months. The BCR rate was 30 % with a 5-year BCR-free survival of 83.9 %. The factors significantly associated with BCR were preoperative PSA, predominance and percentage of Gleason 4, tumor volume, PSM length and predominance of Gleason 4 at the margin. In the multivariate analysis, the remaining two significant factors were PSM length [OR 4.35, 95 % CI (1.011-1.421), p = 0.037] and tumor volume [OR 4.29, 95 % CI (1.011-1.483), p = 0.038]. CONCLUSION: Over a 5-year follow-up, only one-third of patients experienced BCR. It might be reasonable to postpone adjuvant radiotherapy for patients with PSM and undetectable PSA after RP. Tumor volume and PSM length were associated with BCR and should be taken into account in the postoperative treatment management.
Authors: Hemamali Samaratunga; Rodolfo Montironi; Lawrence True; Jonathan I Epstein; David F Griffiths; Peter A Humphrey; Theo van der Kwast; Thomas M Wheeler; John R Srigley; Brett Delahunt; Lars Egevad Journal: Mod Pathol Date: 2010-09-10 Impact factor: 7.842
Authors: Katia R M Leite; Carolina Hartmann; Sabrina T Reis; Nayara Viana; Marcos F Dall'Oglio; Alexandre C Sant'Anna; Adriano Nesrallah; Luciano Nesrallah; Alberto A Antunes; Luiz H Camara-Lopes; Miguel Srougi Journal: Int Braz J Urol Date: 2014 Mar-Apr Impact factor: 1.541
Authors: Gerald W Hull; Farhang Rabbani; Farhat Abbas; Thomas M Wheeler; Michael W Kattan; Peter T Scardino Journal: J Urol Date: 2002-02 Impact factor: 7.450
Authors: Richard Savdie; Lisa G Horvath; Ruth Pe Benito; Krishan K Rasiah; Anne-Maree Haynes; Mark Chatfield; Phillip D Stricker; Jennifer J Turner; Warwick Delprado; Susan M Henshall; Robert L Sutherland; James G Kench Journal: BJU Int Date: 2011-10-12 Impact factor: 5.588
Authors: L Cormier; C Bastide; P Beuzeboc; G Fromont; C Hennequin; P Mongiat-Artus; M Peyromaure; G Ploussard; R Renard-Penna; P Richaud; F Rozet; M Soulié; L Salomon Journal: Prog Urol Date: 2013-12-09 Impact factor: 0.915
Authors: S Guérif; I Latorzeff; J-L Lagrange; C Hennequin; S Supiot; A Garcia; P François; M Soulié; P Richaud; L Salomon Journal: Cancer Radiother Date: 2014-09-05 Impact factor: 1.018
Authors: A Hervás; A Gómez-Caamaño; M Casaña; A Gómez-Iturriaga; J Pastor; J Jove; J L Mengual; C Gónzalez-San Segundo; J Muñoz Journal: Clin Transl Oncol Date: 2017-06-30 Impact factor: 3.405
Authors: Georgios Hatzichristodoulou; Stefan Wagenpfeil; Gudrun Wagenpfeil; Tobias Maurer; Thomas Horn; Kathleen Herkommer; Marie Hegemann; Jürgen E Gschwend; Hubert Kübler Journal: World J Urol Date: 2015-09-29 Impact factor: 4.226
Authors: Christian P Meyer; Jens Hansen; Katharina Boehm; Derya Tilki; Firas Abdollah; Quoc-Dien Trinh; Margit Fisch; Guido Sauter; Markus Graefen; Hartwig Huland; Felix K H Chun; Sascha A Ahyai Journal: World J Urol Date: 2016-06-03 Impact factor: 4.226
Authors: Serdar Celik; Anıl Eker; İbrahim Halil Bozkurt; Deniz Bolat; İsmail Basmacı; Ertuğrul Şefik; Tansu Değirmenci; Bülent Günlüsoy Journal: Prostate Int Date: 2020-09-17